Verily, a subsidiary of Alphabet specializing in precision health technology, and Kyverna Therapeutics, a clinical-stage cell therapy company focused on developing therapies for autoimmune diseases, have announced a multi-year collaboration aimed at identifying novel biomarkers and innovating clinical trial design and execution.

The initial phase of the partnership will involve utilizing Verily's advanced immune mapping platform, known as Immune Profiler, to identify biomarkers of treatment response in autoimmune patients undergoing treatment with Kyverna's KYV-101. KYV-101 is an autologous Chimeric Antigen Receptor (CAR) T-cell therapy currently undergoing Phase 1 clinical trials in the United States and Europe for the treatment of autoimmune diseases.

Charlie Kim, Head of Molecular Science at Verily, stated, "B cell depletion using CAR T-cells represents a new frontier with curative potential for autoimmune patients, and together we will be uncovering the biological basis of the immune reset that confers durable therapeutic response in these patients."

The Immune Profiler platform provides high-resolution molecular phenotyping and advanced computational analytics, enabling a comprehensive examination of immune functions throughout the course of CAR T-cell therapy. This approach offers unprecedented insights into biological activity during treatment. Kyverna will contribute a network of research-ready participants and a growing sample library collected from autoimmune patients treated with KYV-101 in various regions and for multiple indications.

James Chung, Chief Medical Officer at Kyverna, expressed excitement about exploring the emerging patient data set, which will provide valuable insights into the biology underlying immune reset following CAR T-cell therapy administration.

As part of their collaboration, Verily and Kyverna will integrate digital tools and technology solutions to reframe evidence generation. This will involve a participant-centered study design that collects data not only from clinical trial sites but also from real-world settings. Specifically, they will develop solutions tailored to the unique needs of autoimmune patients receiving CAR T-cell therapy.

Peter Maag, CEO of Kyverna, emphasized their shared vision to shape the future of clinical research and enhance data collection from real-world settings, potentially contributing to regulatory decision-making.

Amy Abernethy, President of Product Development and Chief Medical Officer at Verily, highlighted how the collaboration combines Verily's deep molecular expertise with its extensive tools for real-world evidence generation, offering a comprehensive understanding of the biology and participant experience with this innovative therapeutic approach in autoimmune diseases.

Report Abuse